The content on this site is intended for healthcare professionals only
Dr Cusnir presents the highlights of the significant findings in gastrointestinal GL tumors, focusing on four key studies.
It reviews the Checkmate 557 study on nivolumab's role after chemoradiation in esophageal cancers. The Matterhorn study shows durvalumab's impact on survival rates. It also discusses treatments for HER2 positive patients, including trastuzumab Deruxtecan.
Future research aims to ensure equitable benefits and explore new targeted therapies to enhance patient outcomes.
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Understanding Ghana's FDA and pharmacovigilance regulations
Key Insights from ASCO 2024
Geriatric interventions are beneficial in reducing treatment-related toxicity in older adults with cancer
Cancer in emergencies: What can we do better to protect the most vulnerable?
Tele-mentoring: Impact of project ECHO
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Interpreting the results of a clinical trial
Early breast cancer: Treatment pattern
